Adjuvant chemotherapy for resected duodenal adenocarcinoma: a case-matched analysis in nation wide cohort.
Duodenal
adenocarcinoma
adjuvant
chemotherapy
survival
Journal
Acta chirurgica Belgica
ISSN: 0001-5458
Titre abrégé: Acta Chir Belg
Pays: England
ID NLM: 0370571
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
medline:
15
9
2023
pubmed:
22
6
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
Duodenal adenocarcinoma (DA) is a rare tumor for which survival data on adjuvant chemotherapy in patients after surgical treatment are unclear. This case-matched study in a nationwide cohort aims to investigate the benefit of adjuvant chemotherapy for patients with resectable DA on overall survival. All patients diagnosed with DA and intestinal type periampullary adenocarcinoma (PVA) in the Netherlands between 2000 and 2015 were included ( The median OS was 49.9 months in patients who underwent curative resection ( This population-based, case-matched analysis demonstrates no statistically significant survival benefit for adjuvant chemotherapy after curative resection in stages II and III patients. Future studies with specified treatment regimens as well as thorough stratification for prognostic factors will be required in order to more definitively determine the role of adjuvant therapy.
Sections du résumé
BACKGROUND
UNASSIGNED
Duodenal adenocarcinoma (DA) is a rare tumor for which survival data on adjuvant chemotherapy in patients after surgical treatment are unclear. This case-matched study in a nationwide cohort aims to investigate the benefit of adjuvant chemotherapy for patients with resectable DA on overall survival.
METHODS
UNASSIGNED
All patients diagnosed with DA and intestinal type periampullary adenocarcinoma (PVA) in the Netherlands between 2000 and 2015 were included (
RESULTS
UNASSIGNED
The median OS was 49.9 months in patients who underwent curative resection (
CONCLUSION
UNASSIGNED
This population-based, case-matched analysis demonstrates no statistically significant survival benefit for adjuvant chemotherapy after curative resection in stages II and III patients. Future studies with specified treatment regimens as well as thorough stratification for prognostic factors will be required in order to more definitively determine the role of adjuvant therapy.
Identifiants
pubmed: 35727126
doi: 10.1080/00015458.2022.2092961
pii: 10.1080/00015458.2022.2092961
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM